What is Eli Lilly testing in adolescents with obesity, and how would it work? According to a ClinicalTrials.gov record updated June 18, 2026, the company is running a Phase 3 study of orforglipron — an investigational, once-daily oral GLP-1 receptor agonist — against placebo in participants aged 12 to 17 who have obesity, or who are overweight with weight-related comorbidities. The trial carries the registry identifier NCT06672939 and the study acronym ADVANCE-ATTAIN-ADOLESCENTS.

The distinction that matters here is the route of administration. The GLP-1 drugs that have reshaped obesity care to date — the semaglutide and tirzepatide franchises — are injectables. Orforglipron is a small molecule taken as a daily pill. For a teenage population, where needle aversion and adherence are practical concerns clinicians cite, the oral format is the feature being studied. The registry record frames the study as a defined-objective efficacy and safety evaluation rather than a marketing claim.

"The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months."— ClinicalTrials.gov, source

The design module on the record describes a randomized, parallel-assignment trial with double masking — both participants and investigators are listed as masked. Two arms are registered: an experimental orforglipron arm, in which the record states "Participants will receive orforglipron orally," and a placebo-comparator arm, in which "Participants will receive placebo orally." Estimated enrollment is 150 participants. Eligibility is open to all sexes, ages 12 through 17 years, and the record marks healthy volunteers as not accepted — the study population is defined by the obesity or overweight-with-comorbidity criteria, not by general health.

What the endpoint actually measures

Here is what the record actually says the trial is measuring. The single listed primary outcome is "Percent Change from Baseline in Body Mass Index (BMI)," assessed at the time frame "Baseline, Week 72." That choice of metric is worth unpacking in plain terms. In adult obesity trials, percent change in body weight is the conventional headline number. In a pediatric and adolescent population that is still growing, raw weight is a moving target, so BMI — and in many pediatric studies, BMI relative to growth norms — is the standard way to express whether an intervention is changing body composition over time. The registry record specifies BMI percent change as the primary measure and Week 72 as the assessment point; it does not report a result, because the trial is in progress.

The status module lists the overall status as recruiting, with a start date of November 18, 2024, a study-first-posted date of November 4, 2024, and an estimated primary completion date of December 2027. The record was last updated and posted on June 18, 2026. The brief summary also notes a longer-term extension: participants who complete the primary PW01 study, including a four-week safety follow-up, "will have the opportunity to receive an additional 156 weeks of treatment with orforglipron as well as continuing the lifestyle intervention." That is roughly three additional years of optional treatment layered on top of the core study, and the inclusion of a lifestyle intervention alongside the drug is stated in the record.

The master-protocol structure is a detail generalist readers can miss but should notice. The summary states the study is performed under Master Protocol J4M-MC-PWMP, registered separately as NCT06672549. In plain terms, a master protocol is an umbrella framework that lets a sponsor run multiple related sub-studies — different populations, doses, or comparisons — under one coordinated design rather than as wholly independent trials. The adolescent study registered here sits inside that broader orforglipron development program. Strip away the program nomenclature and the practical point is that this adolescent trial is one defined piece of a larger, sponsor-coordinated effort, and the registry links the two records explicitly.

Where this sits in the GLP-1 landscape

The obesity-drug field is currently defined by the injectable incumbents and by the question of whether an effective oral option can broaden access and adherence. Lilly's own injectable, tirzepatide, anchors one side of that franchise, and a separate ClinicalTrials.gov record updated the same day describes a Phase 3 tirzepatide study in adolescents with obesity (NCT06439277). Orforglipron is the oral candidate in the same therapeutic neighborhood. Reading the registry record without editorializing, the relevant facts are these: it is a daily pill, it is being tested against placebo, the population is adolescents, the masking is double, and the efficacy question is framed as percent change in BMI at Week 72.

For readers tracking the sector, the registry entry is the primary document, and it is deliberately narrow about what it claims. It does not assert effectiveness; it specifies what will be measured and how. The estimated 150-participant enrollment is modest relative to the large adult cardiometabolic outcome trials in this space, which is consistent with an adolescent efficacy-and-safety study rather than an outcomes trial powered for cardiovascular events. The 18-month core duration plus the optional 156-week extension signals that durability of effect, not just peak BMI change, is part of what the program is set up to observe over time.

The trial is recruiting, with primary completion estimated for December 2027, so any efficacy data are years away. What the June 18, 2026 record establishes today is the existence, structure, and stated objectives of a Phase 3 oral-GLP-1 study in a younger population — one piece of evidence in the broader question of how metabolic medicine extends to adolescents, documented in a public government registry that readers can consult directly.